Base case cost-effectiveness results for usage of UKR subgroups
| TKR | UKR | ∆ QALYs | ∆ Costs (£) | ICER (probability UKR cost-effective*) | |||
| QALYs | Costs (£) | QALYs | Costs (£) | ||||
| UKR <10% | 8.67 (8.53 to 8.80) | 13 267 (12 834 to 13 731) | 8.62 (8.38 to 8.84) | 13 140 (12 643 to 13 614) | −0.04 (−0.32 to 0.21) | −127 (−429 to 127) | £3000/QALY (37%) |
| UKR ≥10% | 8.81 (8.73 to 8.88) | 13 170 (12 726 to 13 614) | 9.06 (8.94 to 9.18) | 12 411 (11 978 to 12 856) | 0.26 (0.12 to 0.40) | −758 (−939 to −579) | UKR dominant (100%) |
Expected (mean) values with 95% CIs in parentheses. UKR is considered ‘dominant’ if it is expected to improve health outcomes and reduce healthcare costs.
*Given a cost-effectiveness threshold of £20 000.
ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years; TKR, total knee replacement; UKR, unicompartmental knee replacement.